Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

PURPOSE: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolumab in patients with locally advanced or metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Rixe, Olivier, Chiu, Vi K., Forde, Patrick M., Dragovich, Tomislav, Lou, Yanyan, Nayak-Kapoor, Asha, Leidner, Rom, Atkins, James N., Collaku, Agron, Fox, Floyd E., Marshall, Margaret A., Olszanski, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401557/
https://www.ncbi.nlm.nih.gov/pubmed/34753777
http://dx.doi.org/10.1158/1078-0432.CCR-21-2781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401557/
https://www.ncbi.nlm.nih.gov/pubmed/34753777
http://dx.doi.org/10.1158/1078-0432.CCR-21-2781

Ejemplares similares